March 2015 Vol. 3 No. 3

Search Pubmed for articles by:
 

Original Research Article

The clinical research of ¹⁸F-FDG PET/CT in peripheral lung cancer

MingMing YU Ph.D, *Zhen Guang Wang MD., Yan Kong BS, Yue Hua Chen MS and Qian Yu MS

PET/CT Center, Affiliated Hospital of Qingdao University, No. 59, Haier Rd., Qingdao 266100, China

*Corresponding Author’s E-mail: ymmcyh@126.com
Tel: 18661803816

Accepted March 16, 2015

Abstract

This retrospective study aimed to evaluate the ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography (PET)/ computed tomography (CT) imaging characteristics of peripheral lung cancer. 50 patients with peripheral lung cancer confirmed by biopsy and pathology were examined by ¹⁸F-FDG PET/CT. A retrospective study was performed to evaluate the difference of the maximum standardized uptake value (SUVmax) in selected regions of interest (ROI) between adenocarcinoma and squamous cell carcinoma, and the correlation between ROI’s SUVmax and tumor sizes. Studies were interpreted by 2 experienced radiologists. Positive rate for malignant was about 92% and negative rate was about 8% when the SUVmax of 2.5 is used for the cut off point. There were significant differences (p＜0.05）between the SUVmax of adenocarcinoma and that of squamous cell carcinoma. The sizes of 50 cases of peripheral lung cancer were correlated with the SUVmax (r=0.674，p＜0.001) in ROI. ¹⁸F-FDG PET/CT demonstrates an excellent performance in diagnosing lung cancer. The combination of anatomic and metabolic imaging provides valuable information for the clinic.

Keywords: Peripheral lung cancer, positron emission tomography/computed tomography (PET/CT), ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG)